Facts and myths on recurrent vulvovaginal candidosis -: a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy

被引：97

作者：

Mårdh, PA ^{[1
]}

Rodrigues, AG ^{[1
]}

Genç, M ^{[1
]}

Novikova, N ^{[1
]}

Martinez-de-Oliveira, J ^{[1
]}

Guaschino, S ^{[1
]}

机构：

[1] Lund Univ, Dept Obstet & Gynecol, Lund, Sweden

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 2002年 / 13卷 / 08期

关键词：

recurrent vulvovaginal candidosis; epidemiology; diagnosis; pathogenesis; therapy;

D O I：

10.1258/095646202760159639

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Approximately three-quarters of all women will experience an episode of vulvovaginal candidosis at least once in their life and 5-10% of them will have more than one attack. Women suffering from three to four attacks within 12 month,,, will be diagnosed with recurrent vulvovaginal candidosis (RVVC). This review covers the large number of proposed aetiological factors for RVVC. The diagnosis Of the condition made by conventional means by health providers is often false and is also often misdiagnosed by the affected woman herself. The review covers various methods of diagnosing RVVC and the current knowledge on potential pathogenetic mechanisms proposed for genital candida infunctions. Treatment of RVVC, including local and systemic antimicrobial therapy and behaviour modification to decrease the risk of recurrences, are discussed. Recent knowledge on drug resistance in candida is also included.

引用

页码：522 / 539

页数：18

共 190 条

[81] THE SPERMICIDAL COMPOUND NONOXYNOL-9 INCREASES ADHESION OF CANDIDA SPECIES TO HUMAN EPITHELIAL-CELLS INVITRO [J].